The FDA has approved The Medicines Company’s ca channel blocker Cleviprex for the IV treatment of hypertension
Filed under: Calcium Channel | Tagged: AstraZeneca, ca channel, Calcium Channel, Clevelox, Clevidipine, Cleviprex, The Medicines Company | Leave a Comment »
Data presented at the SCA Meeting show The Medicine Company’s Calcium channel antagonist Cleviprex injectable may reduce the risk of heart attack compared to two other antihypertensive agents.
Filed under: Calcium Channel | Tagged: AstraZeneca, ca channel, Calcium Channel, Clevidipine, Cleviprex, Medicine Company | Leave a Comment »
AstraZeneca have expanded their collaboration with Cellectricon. AstraZeneca will install two Dynaflow high throughput ion channel screening systems.
Filed under: Ion Channel | Tagged: AstraZeneca, Cellectricon, Ion Channel, Research | Leave a Comment »
